Hni-Hirudin
Hirudo nipponia salivary-gland hirudin variant identified by transcriptome + in situ hybridisation — Kim 2024 and Shi 2023 (Pichia pastoris recombinant production, 14,000 ATU/mL).
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Hirudo nipponia salivary-gland hirudin variant identified by transcriptome + in situ hybridisation — Kim 2024 and Shi 2023 (Pichia pastoris recombinant production, 14,000 ATU/mL).
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Bleeding
Clinical translation limit
Hni-Hirudin's antithrombin activity in recombinant assays does NOT establish clinical efficacy. No FDA-approved derivative; H. nipponia is not on the FDA K040187 cleared device species list.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 7,000 Da
- Source species
- Hirudo nipponia
- Discovered
- 2023 · Shi P et al.; Kim JH et al.
Biological Targets
- → thrombin (Factor IIa)
Key Citations
- Shi P et al. (2023), Sci Rep · PMID 36973525
- Kim JH et al. (2024), Dev Comp Immunol · PMID 38158145
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.